The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated
